Metrics as of 10/14/2026, 01:24 PM (Berlin time), refresh in progress.
First Tracks Biotherapeutics Stock
First Tracks Biotherapeutics Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Daniel R. Faga
- Employees
- 104
- Market cap
- $1.1 B
- IPO
- 20/04/2026
First Tracks Biotherapeutics Inc is a healthcare company in the biotechnology industry, headquartered in San Diego, US. Led by CEO Daniel R. Faga, the firm specializes in pioneering new immunology-based treatments. The company is actively involved in the discovery and progression of therapeutics aimed at combating…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
First Tracks Biotherapeutics stock: price history
1D
-7.0%
1W
+0.9%
1M
-13.1%
6M
+29.0%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Ask the agents about First Tracks Biotherapeutics
Analyst assessment of First Tracks Biotherapeutics
PRICE TARGET LOW
US$46.00
CONSENSUS
US$68.80
MEDIAN
US$65.00
PRICE TARGET HIGH
US$100.00
No current analyst ratings available.
First Tracks Biotherapeutics stock metrics
P/E
-13.26
P/B
6.64
EV/EBITDA
-10.77
RETURN ON EQUITY
-19.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.6%
FLOAT SHARES
30,223,083
AVG. DAILY VOLUME (30D)
988,547
Insider transactions (SEC)
Orwin John A
Ware J. Anthony
Ware J. Anthony
Marquet Magda
FENTON DENNIS M
Institutional holders
Comparable stocks
Frequently asked questions about First Tracks Biotherapeutics stock
What does First Tracks Biotherapeutics do?
First Tracks Biotherapeutics Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Daniel R. Faga, the company employs around 104 people.
The IPO was on 20/04/2026; the stock trades on NASDAQ under the ticker TRAX.
What do analysts say about First Tracks Biotherapeutics stock?
The average price target is US$68.80, ranging from US$46.00 to US$100.00, with a median of US$65.00.
This is an external assessment, not a statement by Market Jury.
Does First Tracks Biotherapeutics pay a dividend?
No, First Tracks Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to First Tracks Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get First Tracks Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess First Tracks Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.